134 related articles for article (PubMed ID: 31268309)
1. A- and D-Ring Structural Modifications of an Androsterone Derivative Inhibiting 17β-Hydroxysteroid Dehydrogenase Type 3: Chemical Synthesis and Structure-Activity Relationships.
Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D
J Med Chem; 2019 Aug; 62(15):7070-7088. PubMed ID: 31268309
[TBL] [Abstract][Full Text] [Related]
2. Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Djigoué GB; Kenmogne LC; Roy J; Maltais R; Poirier D
Bioorg Med Chem; 2015 Sep; 23(17):5433-51. PubMed ID: 26277760
[TBL] [Abstract][Full Text] [Related]
3. 16-Picolyl-androsterone derivative exhibits potent 17β-HSD3 inhibitory activity, improved metabolic stability and cytotoxic effect on various cancer cells: Synthesis, homology modeling and docking studies.
Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D
J Steroid Biochem Mol Biol; 2021 Jun; 210():105846. PubMed ID: 33609690
[TBL] [Abstract][Full Text] [Related]
4. Impact of androstane A- and D-ring inversion on 17β-hydroxysteroid dehydrogenase type 3 inhibitory activity, androgenic effect and metabolic stability.
Cortés-Benítez F; Roy J; Maltais R; Poirier D
Bioorg Med Chem; 2017 Apr; 25(7):2065-2073. PubMed ID: 28254377
[TBL] [Abstract][Full Text] [Related]
5. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Maltais R; Fournier MA; Poirier D
Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.
Kenmogne LC; Roy J; Maltais R; Rouleau M; Neveu B; Pouliot F; Poirier D
PLoS One; 2017; 12(2):e0171871. PubMed ID: 28182747
[TBL] [Abstract][Full Text] [Related]
7. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship.
Tchédam Ngatcha B; Luu-The V; Labrie F; Poirier D
J Med Chem; 2005 Aug; 48(16):5257-68. PubMed ID: 16078844
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Djigoué GB; Kenmogne LC; Roy J; Poirier D
Bioorg Med Chem Lett; 2013 Dec; 23(23):6360-2. PubMed ID: 24144853
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of a 3β-androsterone derivative as inhibitor of 17β-hydroxysteroid dehydrogenase type 3.
Roy J; Fournier MA; Maltais R; Kenmogne LC; Poirier D
J Steroid Biochem Mol Biol; 2014 May; 141():44-51. PubMed ID: 24434282
[TBL] [Abstract][Full Text] [Related]
10. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
11. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitors: Selectivity, metabolic stability and enhanced potency.
Boutin S; Maltais R; Roy J; Poirier D
Eur J Med Chem; 2021 Jan; 209():112909. PubMed ID: 33081987
[TBL] [Abstract][Full Text] [Related]
13. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
[TBL] [Abstract][Full Text] [Related]
14. Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 3.
Vicker N; Bailey HV; Day JM; Mahon MF; Smith A; Tutill HJ; Purohit A; Potter BVL
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885749
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV
Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334
[TBL] [Abstract][Full Text] [Related]
16. Androsterone derivatives substituted at position 16: chemical synthesis, inhibition of type 3 17beta-hydroxysteroid dehydrogenase, binding affinity for steroid receptors and proliferative/antiproliferative activity on Shionogi (AR+) cells.
Tchédam-Ngatcha B; Luu-The V; Poirier D
J Enzyme Inhib Med Chem; 2002 Jun; 17(3):155-65. PubMed ID: 12443041
[TBL] [Abstract][Full Text] [Related]
17. Development of 17β-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy.
Ning X; Yang Y; Deng H; Zhang Q; Huang Y; Su Z; Fu Y; Xiang Q; Zhang S
Steroids; 2017 May; 121():10-16. PubMed ID: 28267564
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 5α-androstane-17-spiro-δ-lactones with a 3-keto, 3-hydroxy, 3-spirocarbamate or 3-spiromorpholinone as inhibitors of 17β-hydroxysteroid dehydrogenases.
Djigoué GB; Ngatcha BT; Roy J; Poirier D
Molecules; 2013 Jan; 18(1):914-33. PubMed ID: 23344201
[TBL] [Abstract][Full Text] [Related]
19. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.
Bydal P; Luu-The V; Labrie F; Poirier D
Eur J Med Chem; 2009 Feb; 44(2):632-44. PubMed ID: 18472187
[TBL] [Abstract][Full Text] [Related]
20. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV
Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
